← All indications
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
Drugs by status
Approved for this indication (6)
Phase 4 trials (17)
Phase 3 trials (42)
- methylprednisolone
- dexrazoxane
- aldoxorubicin
- venetoclax
- calaspargase pegol
- clofarabine
- nelarabine
- tacrolimus
- hydrocortisone
- lestaurtinib
- levocarnitine
- leucovorin
- allogeneic stem cells
- muromonab cd3
- pegaspargase
- ponatinib
- ifosfamide
- allogeneic hematopoietic stem cells
- sirolimus
- cyclosporine
- mycophenolate
- Anti-thymocyte Globulin (Rabbit)
- nicotinamide
- glucarpidase
- allogeneic cord blood
- cd19 car-t cells
- autologous umbilical cord blood
- mesna
- methotrexate
- vindesine
- +12 more
Phase 2 trials (121)
- allopurinol
- decitabine
- azacitidine
- cmv-specific t-cells
- allogeneic natural killer cells
- plerixafor
- sorafenib
- bendamustine
- bkt-140
- busulfan
- moxetumomab pasudotox
- lenalidomide
- temsirolimus
- cdx-301
- etanercept
- entinostat
- olutasidenib
- obinutuzumab
- aciclovir
- trametinib
- hemopoietic stem cell
- aldesleukin
- beclomethasone
- idasanutlin
- idelalisib
- imiquimod
- Filgrastim
- nivolumab
- bosutinib
- pembrolizumab
- +91 more
Phase 1 trials (109)
- 19-28z t cells
- 7-hydroxystaurosporine
- afatinib
- apolizumab
- olaparib
- becatecarin
- belinostat
- bms-214662
- bpx-501
- carfilzomib
- diphenhydramine
- devimistat
- deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins
- ibuprofen
- valproic acid
- selinexor
- enzalutamide
- fluorouracil
- gnkg168
- gti-2040
- in111 anti-cd45 monoclonal antibody bc8
- bc8
- ispinesib
- ixazomib
- ribociclib
- lenvatinib
- alisertib
- palbociclib
- pegcrisantaspase
- perifosine
- +79 more
Organizations
Organization Involved with Phase 2 Indications (10)
- Celgene
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- Institut de Cancérologie de la Loire (ICLN)
- Medical College of Wisconsin
- University of Southern California
- Federal University of Rio de Janeiro
- Rio de Janeiro Federal University
- Blood and Marrow Transplant Clinical Trials Network
Organization Involved with Phase 1 Indications (1)